Early 3‑day course of remdesivir for the prevention of the progression to severe COVID‑19 in the elderly: A single‑centre, real‑life cohort study

Remdesivir, a viral RNA polymerase inhibitor, has constituted a key component of therapeutic regimens against the pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Originally approved for administration in hospitalized patients, remdesivir leads to improved outcomes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgakopoulou, Vasiliki Epameinondas, Gkoufa, Aikaterini, Makrodimitri, Sotiria, Basoulis, Dimitrios, Tsakanikas, Aristeidis, Karamanakos, Georgios, Mastrogianni, Elpida, Voutsinas, Pantazis M., Spandidos, Demetrios A., Papageorgiou, Chrysovalantis V., Gamaletsou, Maria N., Sipsas, Nikolaos V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469144/
https://www.ncbi.nlm.nih.gov/pubmed/37664680
http://dx.doi.org/10.3892/etm.2023.12161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469144/
https://www.ncbi.nlm.nih.gov/pubmed/37664680
http://dx.doi.org/10.3892/etm.2023.12161

Ejemplares similares